Abstract
BackgroundIL17 inhibitors have proven to reduce disease activity in patients with ankylosing spondylitis (AS). AS is an intriguing disease which is characterized by both excessive bone formation and bone loss....
Full Text 
Sign-in/Register to access full text options
Sign-in/Register to access full text options 
Published version (
Free)
Free) 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call
